Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
April 1, 2016
- Eisai Gives Rights for Cancer Drug to Dr. Reddy’s Outside Japan, Asia
April 1, 2016
- Gilead Files Japan NDA for Tenofovir Prodrug for Chronic Hep B
April 1, 2016
- Janssen Seeks MCL Indication for Imbruvica
April 1, 2016
- HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
March 31, 2016
- Eisai Transfers Thrombocytopenia Drug to US Investment Firm
March 31, 2016
- Janssen Files Stelara for Crohn’s Disease
March 31, 2016
- EA Pharma to Start Up with 440 Sales Reps, Offer 24 Products
March 31, 2016
- Kyorin, Kissei to Jointly Develop, Market OAB Treatment
March 31, 2016
- Santen Gets Worldwide Rights to Ono’s FP and EP3 Dual Receptor Agonist
March 31, 2016
- Shionogi Files Japan, US NDAs for Naldemedine for Opioid-Induced Constipation
March 31, 2016
- Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
March 30, 2016
- Astellas, Mitsubishi Tanabe to Share Compound Libraries
March 30, 2016
- In a Setback, FDA Rebuffs Label Expansion for Takeda’s Brintellix
March 30, 2016
- PeptiDream, Asahi Kasei Pharma Forge Research Collaboration
March 29, 2016
- Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
- ASKA Shoots for Group Annual Sales of 70 Billion Yen in Five Years
March 29, 2016
- Asian PII Study Launched for Solasia’s PTCL Treatment: Meiji Seika Pharma
March 29, 2016
- Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
March 28, 2016
- IP High Court Rules in Favor of Chugai in Oxarol Patent Suit
March 28, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…